YOUR BUSINESS AUTHORITY

Springfield, MO

Log in Subscribe

Fresenius to buy Akorn for $4.3B

Posted online
Germany’s Fresenius SE agreed to buy Illinois-based generic drugmaker Akorn Inc. for $4.3 billion.

Including debt, the Akorn deal has an enterprise value of $4.75 billion.

Separately, Fresenius announced plans to buy Merck KGaA’s portfolio of biosimilars, which are copycat versions of complex biotechnology drugs, for $184.7 million, plus licensing fees.

Read more from Bloomberg.


Comments

No comments on this story |
Please log in to add your comment
Editors' Pick
Annual downtown holiday events combine for Nov. 21 celebration

Organizers hope to bolster client traffic to center city businesses.

Most Read
Update cookies preferences